IN2014DN09221A - - Google Patents
Info
- Publication number
- IN2014DN09221A IN2014DN09221A IN9221DEN2014A IN2014DN09221A IN 2014DN09221 A IN2014DN09221 A IN 2014DN09221A IN 9221DEN2014 A IN9221DEN2014 A IN 9221DEN2014A IN 2014DN09221 A IN2014DN09221 A IN 2014DN09221A
- Authority
- IN
- India
- Prior art keywords
- inhibitor
- chk1
- compounds
- present
- kinase function
- Prior art date
Links
- 102000006459 Checkpoint Kinase 1 Human genes 0.000 abstract 5
- 108010019244 Checkpoint Kinase 1 Proteins 0.000 abstract 5
- 239000003112 inhibitor Substances 0.000 abstract 5
- 150000001875 compounds Chemical class 0.000 abstract 3
- 108010022394 Threonine synthase Proteins 0.000 abstract 2
- 102000005497 Thymidylate Synthase Human genes 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 102000052567 Anaphase-Promoting Complex-Cyclosome Apc1 Subunit Human genes 0.000 abstract 1
- 108700004581 Anaphase-Promoting Complex-Cyclosome Apc1 Subunit Proteins 0.000 abstract 1
- 102000003915 DNA Topoisomerases Human genes 0.000 abstract 1
- 108090000323 DNA Topoisomerases Proteins 0.000 abstract 1
- 230000005778 DNA damage Effects 0.000 abstract 1
- 231100000277 DNA damage Toxicity 0.000 abstract 1
- 230000005971 DNA damage repair Effects 0.000 abstract 1
- 239000012623 DNA damaging agent Substances 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- 102000007537 Type II DNA Topoisomerases Human genes 0.000 abstract 1
- 108010046308 Type II DNA Topoisomerases Proteins 0.000 abstract 1
- 230000001668 ameliorated effect Effects 0.000 abstract 1
- 230000000340 anti-metabolite Effects 0.000 abstract 1
- 229940100197 antimetabolite Drugs 0.000 abstract 1
- 239000002256 antimetabolite Substances 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 230000011278 mitosis Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 230000005855 radiation Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261647200P | 2012-05-15 | 2012-05-15 | |
| PCT/GB2013/051233 WO2013171470A1 (en) | 2012-05-15 | 2013-05-14 | 5-[[4-[[morpholin-2-yl]methylamino]-5-(trifluoromethyl)-2-pyridyl]amino]pyrazine-2-carbonitrile and therapeutic uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014DN09221A true IN2014DN09221A (de) | 2015-07-10 |
Family
ID=48468659
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN9221DEN2014 IN2014DN09221A (de) | 2012-05-15 | 2013-05-14 |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US9663503B2 (de) |
| EP (2) | EP2855448B1 (de) |
| JP (2) | JP6027230B2 (de) |
| KR (6) | KR102341637B1 (de) |
| CN (2) | CN104302635B (de) |
| AU (2) | AU2013261605B2 (de) |
| BR (1) | BR112014026801B1 (de) |
| CA (1) | CA2870837C (de) |
| DK (1) | DK2855448T3 (de) |
| ES (2) | ES2981584T3 (de) |
| HK (2) | HK1203529A1 (de) |
| IL (1) | IL235133A (de) |
| IN (1) | IN2014DN09221A (de) |
| MX (1) | MX358819B (de) |
| NZ (1) | NZ702050A (de) |
| PL (1) | PL2855448T3 (de) |
| RU (1) | RU2659786C2 (de) |
| SG (1) | SG11201407238VA (de) |
| WO (1) | WO2013171470A1 (de) |
| ZA (1) | ZA201408452B (de) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9040540B2 (en) | 2011-11-09 | 2015-05-26 | Cancer Research Technology Limited | 5-(pyridin-2-yl-amino)-pyrazine-2-carbonitrile compounds and their therapeutic use |
| KR102341637B1 (ko) | 2012-05-15 | 2021-12-21 | 캔써 리서치 테크놀로지 리미티드 | 5-[[4-[[모르폴린-2-일]메틸아미노]-5-(트리플루오로메틸)-2-피리딜]아미노]피라진-2-카보니트릴 및 그의 치료적 용도 |
| TWI618706B (zh) | 2012-12-07 | 2018-03-21 | 維泰克斯製藥公司 | 用作ａｔｒ激酶抑制劑之化合物 |
| JP2016512815A (ja) | 2013-03-15 | 2016-05-09 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | Ａｔｒキナーゼの阻害剤として有用な縮合ピラゾロピリミジン誘導体 |
| EP3077397B1 (de) | 2013-12-06 | 2019-09-18 | Vertex Pharmaceuticals Inc. | 2-amino-6-fluor-n-5-[fluor-pyridin-3-yl]pyrazol[1,5-a] pyrimidin-3-carboxamid-verbindung als atr-kinaseinhibitor, deren herstellung, unterschiedliche feste formen und radioaktiv markierte derivate davon |
| PT3152212T (pt) | 2014-06-05 | 2020-03-13 | Vertex Pharma | Derivados radiomarcados de um composto de 2-amino-6-fluoro-n-[5-fluoro-piridin-3-il]-pirazolo[1,5-a]pirimidin-3-carboxamida útil como inibidor de atr quinase, preparação do dito composto e diferentes formas sólidas do mesmo |
| NZ727399A (en) * | 2014-06-17 | 2022-07-29 | Vertex Pharma | Method for treating cancer using a combination of chk1 and atr inhibitors |
| EP3355926A4 (de) | 2015-09-30 | 2019-08-21 | Vertex Pharmaceuticals Inc. | Verfahren zur behandlung von krebs mit einer kombination von dna-schädigenden mitteln und atr-inhibitoren |
| WO2018094325A1 (en) * | 2016-11-18 | 2018-05-24 | The Trustees Of Columbia University In The City Of New York | Therapeutic modulation of oncogenes by pharmacologic top2 targeting for cancer |
| US20200108074A1 (en) * | 2017-03-31 | 2020-04-09 | Seattle Genetics, Inc. | Combinations of chk1- and wee1- inhibitors |
| JP7273791B2 (ja) * | 2017-04-10 | 2023-05-15 | シエラ オンコロジー， インコーポレイテッド | 腫瘍成長を阻害するＣＨＫ１（ＳＲＡ７３７）／ＰＡＲＰｉ組み合わせ方法 |
| WO2018191299A1 (en) * | 2017-04-10 | 2018-10-18 | Sierra Oncology, Inc. | Chk1(sra737)wee1 inhibitor combination methods of inhibiting tumor growth |
| US20200157638A1 (en) * | 2017-06-01 | 2020-05-21 | Sierra Oncology, Inc. | Biomarkers and patient selection strategies |
| CN107266897B (zh) * | 2017-08-04 | 2019-05-14 | 上海跃贝新材料科技股份有限公司 | 一种低粘度矿物增强pc/pet合金材料及其制备方法 |
| US20200397796A1 (en) * | 2018-02-26 | 2020-12-24 | Sierra Oncology, Inc. | Methods of treatment of cancer comprising chk1 inhibitors |
| EP3914284A4 (de) * | 2019-01-25 | 2022-10-26 | Numedii, Inc. | Verfahren zur behandlung von idiopathischer lungenfibrose |
| US20220184091A1 (en) * | 2019-03-28 | 2022-06-16 | Sierra Oncology, Inc. | Methods of Treating Cancer with Chk1 Inhibitors |
| US20220226338A1 (en) * | 2019-05-14 | 2022-07-21 | Sierra Oncology, Inc. | Methods of Treating Cancer Using CHK1 Inhibitors |
| CN110872277B (zh) * | 2019-11-14 | 2021-06-04 | 浙江大学 | N-取代芳环-2-氨基嘧啶类化合物及用途 |
| CN110684083B (zh) * | 2019-12-06 | 2020-05-15 | 北京诺赛启研再生医学研究院有限公司 | 抑制黑色素合成的偶联物ii及其在药品和化妆品中的应用 |
| CN110680928B (zh) * | 2019-12-06 | 2020-04-28 | 深圳前海港影生物科技有限公司 | 抑制黑色素合成的偶联物及其在药品和化妆品中的应用 |
| TW202204348A (zh) * | 2020-04-07 | 2022-02-01 | 美商西爾拉癌症醫學公司 | Ｃｈｋ１抑制劑之合成方法 |
| CN117858870A (zh) * | 2021-08-17 | 2024-04-09 | 葛兰素史密斯克莱知识产权(第3号)有限公司 | P2x3拮抗剂的制备 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773778A (en) | 1972-01-24 | 1973-11-20 | Squibb & Sons Inc | Sulfur derivatives of pyrazolo (3,4-b)pyridines |
| IL112248A0 (en) | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
| PT836605E (pt) | 1995-07-06 | 2002-07-31 | Novartis Ag | Pirrolopirimidinas e processos para a sua preparacao |
| WO2003032984A1 (en) | 2001-10-19 | 2003-04-24 | Ortho-Mcneil Pharmaceutical,Inc. | 2-phenyl benzimidazoles and imidazo-[4,5]-pyridines as cdsi/chk2-inhibitors and adjuvants to chemotherapy or radiation therapy in the treatment of cancer |
| BR0213562A (pt) | 2001-10-26 | 2004-08-31 | Aventis Pharma Inc | Benzimidazóis e análogos e seu uso como inibidores de cinases de proteìna |
| EP1442039A1 (de) | 2001-10-31 | 2004-08-04 | Bayer HealthCare AG | Pyrimido(4,5-b)indolderivate |
| EP1501514B1 (de) * | 2002-05-03 | 2012-12-19 | Exelixis, Inc. | Proteinkinasemodulatoren und verfahren zur derer anwendung |
| AU2003243318A1 (en) | 2002-05-29 | 2003-12-19 | Millennium Pharmaceuticals, Inc. | Diarylurea compounds and derivatives as chk-1 inhibitors for the treatment of cancer |
| CN1860118A (zh) | 2003-07-29 | 2006-11-08 | Irm责任有限公司 | 作为蛋白激酶抑制剂的化合物和组合物 |
| MXPA06003996A (es) | 2003-10-08 | 2006-07-05 | Irm Llc | Compuestos y composiciones como inhibidores de la proteina cinasa. |
| DK1678166T3 (da) | 2003-10-14 | 2009-11-09 | Univ Arizona State | Proteinkinaseinhibitorer |
| AU2004281154A1 (en) | 2003-10-16 | 2005-04-28 | Novartis Vaccines And Diagnostics, Inc. | 2,6-disubstituted quinazolines, quinoxalines, quinolines and isoquinolines as inhibitors of Raf kinase for treatment of cancer |
| US7163939B2 (en) | 2003-11-05 | 2007-01-16 | Abbott Laboratories | Macrocyclic kinase inhibitors |
| US20050096324A1 (en) | 2003-11-05 | 2005-05-05 | Zhi-Fu Tao | Macrocyclic kinase inhibitors |
| DE602005019556D1 (de) | 2004-04-13 | 2010-04-08 | Icagen Inc | Polycyclische pyrazine als kaliumionenkanal-modulatoren |
| US20070054916A1 (en) | 2004-10-01 | 2007-03-08 | Amgen Inc. | Aryl nitrogen-containing bicyclic compounds and methods of use |
| JP2008539277A (ja) | 2005-04-28 | 2008-11-13 | スーパージェン， インコーポレイテッド | プロテインキナーゼインヒビター |
| JP5097701B2 (ja) | 2005-06-28 | 2012-12-12 | サノフイ | Ｒｈｏ−キナーゼの阻害剤としてのイソキノリン誘導体 |
| PE20070335A1 (es) | 2005-08-30 | 2007-04-21 | Novartis Ag | Benzimidazoles sustituidos y metodos para su preparacion |
| KR20080063806A (ko) | 2005-10-06 | 2008-07-07 | 쉐링 코포레이션 | 단백질 키나제 억제제로서의 피라졸로피리미딘 |
| US8119655B2 (en) | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| GB0616747D0 (en) * | 2006-08-24 | 2006-10-04 | Astrazeneca Ab | Novel compounds |
| BRPI0721180A2 (pt) | 2006-12-27 | 2014-03-18 | Sanofi Aventis | Derivados de isoquinolina substituídos com cicloalquilamina |
| CA2681015C (en) | 2007-03-16 | 2016-06-21 | The Scripps Research Institute | Inhibitors of focal adhesion kinase |
| WO2008117050A1 (en) | 2007-03-27 | 2008-10-02 | Astrazeneca Ab | Pyrazolyl-amino-substituted pyrazines and their use for the treatment of cancer |
| EP2170886A1 (de) | 2007-07-02 | 2010-04-07 | Cancer Research Technology Limited | 9H-PYRIMIDO[4,5-B]INDOLE, 9H-PYRIDO[4ý,3ý:4,5]PYRROLO[2,3-D]PYRIDINE UND 9H-1,3,6,9-TETRAAZAFLUORENE ALS INHIBITOREN DER FUNKTION VON CHK1-KINASE |
| GB0719644D0 (en) | 2007-10-05 | 2007-11-14 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| GB0803018D0 (en) | 2008-02-19 | 2008-03-26 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| US9040540B2 (en) | 2011-11-09 | 2015-05-26 | Cancer Research Technology Limited | 5-(pyridin-2-yl-amino)-pyrazine-2-carbonitrile compounds and their therapeutic use |
| KR102341637B1 (ko) | 2012-05-15 | 2021-12-21 | 캔써 리서치 테크놀로지 리미티드 | 5-[[4-[[모르폴린-2-일]메틸아미노]-5-(트리플루오로메틸)-2-피리딜]아미노]피라진-2-카보니트릴 및 그의 치료적 용도 |
-
2013
- 2013-05-14 KR KR1020217012299A patent/KR102341637B1/ko active IP Right Grant
- 2013-05-14 ES ES17152400T patent/ES2981584T3/es active Active
- 2013-05-14 PL PL13723910T patent/PL2855448T3/pl unknown
- 2013-05-14 EP EP13723910.9A patent/EP2855448B1/de active Active
- 2013-05-14 NZ NZ702050A patent/NZ702050A/en unknown
- 2013-05-14 BR BR112014026801-0A patent/BR112014026801B1/pt active IP Right Grant
- 2013-05-14 JP JP2015512120A patent/JP6027230B2/ja active Active
- 2013-05-14 AU AU2013261605A patent/AU2013261605B2/en active Active
- 2013-05-14 IN IN9221DEN2014 patent/IN2014DN09221A/en unknown
- 2013-05-14 ES ES13723910.9T patent/ES2624307T3/es active Active
- 2013-05-14 CN CN201380025541.3A patent/CN104302635B/zh active Active
- 2013-05-14 SG SG11201407238VA patent/SG11201407238VA/en unknown
- 2013-05-14 RU RU2014147105A patent/RU2659786C2/ru active
- 2013-05-14 US US14/396,338 patent/US9663503B2/en active Active
- 2013-05-14 KR KR1020247004407A patent/KR20240023685A/ko active Application Filing
- 2013-05-14 MX MX2014012881A patent/MX358819B/es active IP Right Grant
- 2013-05-14 WO PCT/GB2013/051233 patent/WO2013171470A1/en active Application Filing
- 2013-05-14 CN CN201610652725.8A patent/CN106279142B/zh active Active
- 2013-05-14 KR KR1020207007411A patent/KR102246265B1/ko active IP Right Grant
- 2013-05-14 KR KR1020147031572A patent/KR102090792B1/ko active IP Right Grant
- 2013-05-14 DK DK13723910.9T patent/DK2855448T3/en active
- 2013-05-14 CA CA2870837A patent/CA2870837C/en active Active
- 2013-05-14 KR KR1020227037439A patent/KR102635954B1/ko active IP Right Grant
- 2013-05-14 KR KR1020217041302A patent/KR20210156333A/ko not_active Application Discontinuation
- 2013-05-14 EP EP17152400.2A patent/EP3210980B1/de active Active
-
2014
- 2014-10-19 IL IL235133A patent/IL235133A/en active IP Right Grant
- 2014-11-18 ZA ZA2014/08452A patent/ZA201408452B/en unknown
-
2015
- 2015-04-28 HK HK15104108.4A patent/HK1203529A1/xx unknown
-
2016
- 2016-10-13 JP JP2016201383A patent/JP6362652B2/ja active Active
-
2017
- 2017-05-04 US US15/587,270 patent/US10259806B2/en active Active
- 2017-11-28 AU AU2017268508A patent/AU2017268508C1/en active Active
-
2018
- 2018-02-27 HK HK18102805.1A patent/HK1243408A1/zh unknown
-
2020
- 2020-12-17 US US17/124,606 patent/US11787792B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014DN09221A (de) | ||
| ZA201906269B (en) | Compounds useful in the treatment or prevention of a prmt5-mediated disorder | |
| JOP20200342A1 (ar) | مشتقات بيرازين مدمجة كمثبطات a2a/a2b | |
| PH12015501067A1 (en) | Pyrrolopyrimidine compounds as kinase inhibitors | |
| PH12014501815A1 (en) | Purinone compounds as kinase inhibitors | |
| PH12016500575A1 (en) | Inhibitors of bruton`s tyrosine kinase | |
| PH12015500940A1 (en) | Bruton`s tyrosine kinase inhibitors | |
| BR112012022513A2 (pt) | derivados de piperidin-4-il azetidina como inibidores de jak1 | |
| MX2013012981A (es) | Compuestos de indazol sustituidos como inhibidores de las cinasas de proteina. | |
| MX339899B (es) | Compuestos de triazolopiridina como inhibidores de pim cinasa. | |
| MX339937B (es) | Compuestos y composiciones como inhibidores de la quinasa c-kit. | |
| MX342329B (es) | Compuestos y composiciones como inhibidores de la quinasa c-kit. | |
| MX369589B (es) | Derivados novedosos de bencimidazol como inhibidores de cinasas. | |
| GB201104267D0 (en) | Pyrrolopyridineamino derivatives | |
| WO2014179562A8 (en) | 1,3,5-triazinane-2,4,6-trione derivatives and uses thereof | |
| TN2013000348A1 (en) | Compounds and compositions as trk inhibitors | |
| MX2020012376A (es) | Derivados de pirimidina fusionados como inhibidores de los receptores de adenosina a2a/a2b. | |
| UA115983C2 (uk) | Інгібітори днк-пк | |
| MX2009010034A (es) | Pirimidodiazepinas sustituidas utiles inhibidores de la plk1. | |
| MX2014002486A (es) | Compuestos y composiciones como inhibidores de cinasa pdgfr. | |
| BR112013008140A8 (pt) | "compostos imidazotriazinona". | |
| TN2013000325A1 (en) | (1,2,4)triazolo[4,3-a]quinoxaline derivatives as inhibitors of phosphodiesterases | |
| PH12014501829A1 (en) | Bicyclic pyrazinone derivatives | |
| MX362855B (es) | Derivados de quinazolinona como inhidores poli (adp-ribosa) polimerasa (parp). | |
| MX357502B (es) | Derivados de pirrolotriazinona. |